Document is current
Any future updates will be listed below
-
Authors
Paetzold, Jörg https://orcid.org/0000-0003-1894-4432
Kimpel, Janine https://orcid.org/0000-0002-5210-7905
Bates, Katie
Hummer, Michael
Krammer, Florian https://orcid.org/0000-0003-4121-776X
von Laer, Dorothee https://orcid.org/0000-0001-5825-7237
Winner, Hannes https://orcid.org/0000-0001-9350-6892
- License Information
-
More Information
Article History
Received: 24 August 2021
Accepted: 10 January 2022
First Online: 1 February 2022
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. The funders had no role in the design of the study; in the collection or analyses of data, in the writing of the manuscript, or influence on the judgments and actions with regard to objective data presentation and interpretation. Thus, there was no threat to the objectivity, integrity, and value of a publication. For all other authors, no competing interests exist.
